Investigators intend to measure the activity of CYP in an acute inflammation model (hip surgery) and chronic inflammation model (rheumatoid arthritis, RA). The effect of the biological agent tocilizumab (anti IL-6 receptor) in a treated patient subgroup (patients treated regardless of our study) will be measured after 3 months of treatment.